HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...

Curing HIV will be harder than curing cancer. Apart from a few 'miracle' cases, antiretrovirals only suppress HIV, they don't ...

Stanford researchers highlight the potential of EBC-46, a compound derived from Australia’s blushwood tree, in eradicating ...

Under Trump's foreign aid pause, all payments by U.S. Agency for International Development (USAID) stopped on Tuesday - for the first time since the fiscal year began on Oct. 1 - and have not resumed, ...

A move by the Trump administration to freeze funding for PEPFAR, the widely heralded international HIV/AIDS program, is ...

A series of orders from the Trump administration have the potential to disrupt the delivery of life-saving medications to HIV ...

A new chemical compound has been making a big impression in the fight against cancer in recent years. Now it seems EBC-46, otherwise known as tigilanol tiglate, may also have immense potential for ...

Human immunodeficiency virus type 1 (HIV-1) targets important cells of our immune system, making infected individuals more ...

The new administration's freeze on foreign aid (affecting America's sweeping anti-HIV initiative PEPFAR) has raised concerns ...

A unique reaction in which antibodies bind to other antibodies may help scientists at Scripps Research better understand how ...

HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

today announced the opening of the ACACIA study (Antiretrovirals Combined with Antibodies for HIV-1 Cure in Africa), also ...